PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells

S Sixuan Pan I Inés Fernández-Maestre K Kai-Chun Chang S Stéphane Van Haver M Matthew G. Wereski A Alexandra M. Haugh K Katy K. Tsai A Adil I. Daud R Robert L. Bowman (Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center) H Harish N. Vasudevan (Department of Radiation Oncology, University of California San Francisco) R Ross L. Levine A Adam R. Abate

Abstract

Abstract Single-cell transcriptomics is valuable for uncovering individual cell properties, particularly in heterogeneous systems. However, this technique often results in the reanalysis of many well-characterized cells, increasing costs and diluting rare cell populations. To address this, we develop PIP-seq for Rare-cell Enrichment and Sequencing (PURE-seq). PURE-seq allows direct FACS sorting of cells into PIP-seq reactions, minimizing handling and reducing cell loss. PURE-seq reliably sequences ultrarare cells, with 1 hour of sorting capturing tens of target cells at a rarity of 1 in 1,000,000. Leveraging this extreme sensitivity, we use PURE-seq to isolate and single-cell sequence circulating tumor cells from metastatic melanoma patient blood, obtaining detailed single cancer cell gene expression profiles. Additionally, we use PURE-seq to examine hematopoietic stem and progenitor cells from young, old and middle-aged mice. Transcriptomic analysis identifies Egr1 as a putative master regulator of murine hematopoietic stem and progenitor cell aging, demonstrating PURE-seq’s utility as a discovery platform for basic science applications. PURE-seq offers a simple and highly sensitive method for single-cell sequencing ultra-rare cells.

Article Details

Volume / Issue Vol. 17, Issue 1
Published January 21, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (12)

S

Sixuan Pan

I

Inés Fernández-Maestre

K

Kai-Chun Chang

S

Stéphane Van Haver

M

Matthew G. Wereski

A

Alexandra M. Haugh

K

Katy K. Tsai

A

Adil I. Daud

R

Robert L. Bowman

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

H

Harish N. Vasudevan

Department of Radiation Oncology, University of California San Francisco

R

Ross L. Levine

A

Adam R. Abate